SUPN Supernus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%
Returns
ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.24B | $1.19B |
| Cost of revenue | $246.00M | $231.00M |
| Gross profit | $994.00M | $957.00M |
| R&D expense | $97.00M | $107.00M |
| SG&A expense | $634.00M | $612.00M |
| Operating income | $262.00M | $38.00M |
| Interest expense | $45.00M | $41.00M |
| Pretax income | $239.00M | $20.00M |
| Income tax | $29.00M | $13.00M |
| Net income | $210.00M | $7.00M |
| EBITDA | $272.00M | $54.00M |
| EPS (basic) | 1.68 | 0.05 |
| EPS (diluted) | 1.64 | 0.05 |
| Weighted avg. shares (diluted) | 128.00M | 133.00M |
| Balance sheet | ||
| Cash & equivalents | $195.00M | $319.00M |
| Short-term investments | $0 | $1.00M |
| Receivables | $253.00M | $254.00M |
| Inventory | $153.00M | $167.00M |
| Current assets | $652.00M | $827.00M |
| PP&E, net | $144.00M | $100.00M |
| Goodwill | $2.00M | $2.00M |
| Total assets | $1.20B | $1.32B |
| Current liabilities | $914.00M | $924.00M |
| Short-term debt | $29.00M | $18.00M |
| Long-term debt | $290.00M | $315.00M |
| Total debt | $319.00M | $333.00M |
| Total liabilities | $1.30B | $1.65B |
| Shareholders' equity | -$98.00M | -$337.00M |
| Net debt | $124.00M | $14.00M |
| Cash flow statement | ||
| Operating cash flow | -$27.00M | $36.00M |
| Capital expenditure | $66.00M | $29.00M |
| Free cash flow | -$93.00M | $7.00M |
| Investing cash flow | -$66.00M | $69.00M |
| Financing cash flow | -$30.00M | -$102.00M |
| Depreciation & amortization | $10.00M | $16.00M |
| Stock-based compensation | $26.00M | $24.00M |
| Share buybacks | $11.00M | $173.00M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.